← All trials
NCT04354090
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 26, 2018
- Primary completion
- Dec 27, 2018
- Completion date
- Jun 22, 2019
- First posted
- Apr 21, 2020
- Last posted
- Apr 21, 2020
- Enrollment
- 41
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Beijing Dongfang Biotech Co., Ltd.Lead sponsor
- Nanjing UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.